tradmap

AKBA Earnings Akebia Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$3 -$1 $0 $0 2017 2017 2017 2019 2020 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $168M $335M 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$385M -$192M $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$0 -$0 $0 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $31M $62M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$23M -$8M $6M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–30 of 30
Q2 20262026-06-30-0.072026-08-0510-Q
Q1 20262026-03-31-0.032026-05-0710-Q
FY 20252025-12-31-0.022026-02-2610-K
Q3 20252025-09-300.032025-11-1010-Q
Q2 20262025-06-300.022026-08-0510-Q
Q1 20262025-03-310.032026-05-0710-Q
FY 20252024-12-31-0.332026-02-2610-K
Q3 20252024-09-30-0.222025-11-1010-Q
Q2 20252024-06-30-0.132025-08-0710-Q
Q1 20252024-03-31-0.092025-05-0810-Q
FY 20252023-12-31-0.282026-02-2610-K
Q3 20242023-09-30-0.282024-11-0710-Q
Q2 20242023-06-30-0.202024-08-0810-Q
Q1 20242023-03-31-0.152024-05-0910-Q
FY 20232022-12-31-0.522024-03-1410-K
Q3 20232022-09-30-0.482023-11-0810-Q
Q2 20232022-06-30-0.192023-08-2810-Q
Q2 20232022-03-31-0.352023-08-2810-Q
FY 20222021-12-31-1.702023-03-1010-K
Q3 20222021-09-30-1.302022-11-0310-Q
Q2 20222021-06-30-0.972022-08-0410-Q
Q1 20222021-03-31-0.452022-05-0910-Q
FY 20222020-12-31-2.772023-03-1010-K
Q3 20212020-09-30-2.182021-11-0410-Q
Q2 20212020-06-30-1.782021-08-0510-Q
FY 20212019-12-31-2.362022-03-0110-K
FY 20182017-12-310.312019-03-2610-K
FY 20182017-09-30-0.492019-03-2610-K
FY 20182017-06-30-0.532019-03-2610-K
FY 20182017-03-31-1.152019-03-2610-K

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.